Close

Jump to:

  • Navigation
  • Content
  • Footer

OncoStats

Follow

OncoStats is a software that collects Real World Evidence (RWE) in Oncology both in hospital and at home.

0%
 - 
Funded
€250,000 target
€258,090 from 0 investors
More
Less

Business overview

Location Braga, Portugal
Social media
Website www.oncostats.io
Sectors Healthcare Digital Mixed B2B/B2C
Company number -
Incorporation date -
More
Less

Investment summary

Type Equity
Valuation (pre-money) €2.2M
Equity offered 10.00%
Tax relief N/A
  • Idea
  • Market
  • Team
  • Updates
  • Investors 0
  • Discussion
  • Documents

Idea

Introduction

OncoStats aims to be the leading software to change the practice of Oncology.

In short, OncoStats allows clinical information to be registered in a systematic and structured manner in a database, with every piece of registered information being previously validated by a physician. Patients also submit standardized information during ambulatory treatments (patient-related outcomes) and are actively engaged through a dedicated app. The data we gather is then used to produce real-world evidence (RWE) that impacts the way oncology care is delivered.

Please note that the app is currently being developed.

Intended impact

Clinical information is almost entirely stored in the form of unstructured data (e.g. free-form text) inside hospital's databases. Most companies that work with data choose to focus on techniques to create value from these sources, usually Data Mining, which demands huge numbers of individual patient data to combat their imprecise nature. Instead, OncoStats chooses to focus on providing a software platform that is used by doctors every day, improving their workflow in a meaningful way while, at the same time, effortlessly collects valuable, robust and clinically validated information. Objectively, this means that for every 100 individual patient datasets collected with OncoStats, we estimate that Data Mining techniques would need 10,000 individual patient datasets to match the same accuracy and value.

OncoStats has an impact on several dimensions:

- For Oncologists, it means time saved when producing patient reports, it improves the quality of clinical information and reduces the likelihood of errors by supporting decisions on patient staging and choosing the most appropriate therapy for individual patient characteristics.

- For Patients it results in better care received and they are provided with a tool that they can take home during treatments to report adverse effects, receive support and keep in touch with their doctors.

- For Hospital Administrators and Clinical Directors it results in drops in consultation duration times and in costs due to less inappropriate exams being ordered and more accurate diagnosis. They receive better performance indicators which allows their institution to be recognized as an "Excellence/Reference” center, which ultimately brings more patient referrals. They will find it easier to attract deals with Pharmaceuticals for clinical trials and RWE studies.

- For Pharmaceuticals it means quality RWE and drug safety surveillance data is being collected which should allow for better deals with regulatory agencies and governments when negotiating drug prices and copayments.

We have also had interest from Governments and Regulators regarding the product.

Substantial accomplishments to date

We are currently running a real world pilot in a Portuguese public hospital that will integrate with the existing IT ecosystem, coexisting with and complementing the local Electronical Medical Records (EMR) system.

Because the same basic EMR runs in many hospitals in Portugal, a successful pilot has the potential to become a launch platform for nearly every public hospital in the country.

We are also currently running a real world pilot in private hospital from one of the largest healthcare groups in Portugal.

These two hospitals will be our first 2 clients at the end of the pilot duration (early 2017).

By leveraging the capabilities of OncoStats and the unique market conditions in Portugal, we foresee that Portugal will become a centralised hub to collect Real-World Evidence with an impact that resonates in the way Oncology is practiced throughout Europe.

Monetisation strategy

Our target audience is cancer treatment institutions (both public and private hospitals). OncoStats intends to sell software licenses, analytics reports and cement partnerships with Pharmaceuticals (generating RWE pipelines).

The price for licenses is based on several variables: contract duration, number of cancer modules, number of clinical users and number of patients.

The base license price includes an annual automated analytics report for the hospital administration. A customized report to address specific needs (e.g. criteria fulfillment to become a Reference/Excellence Center, clinical trials criteria application, etc.) can be negotiated in the contract.

The number of cancer modules is flexible: for example, an initial contract agreement can be had for a single cancer module (e.g. OncoStats for Breast Cancer) but other modules can be added later in the future at an additional cost.

We intend to cement partnerships between pharmaceuticals and the hospitals that use OncoStats for the collection of RWE, including drug efficiency and safety indicators and adverse events reports.

Use of proceeds

Our strategy for the use of proceeds is the following:

- Team and product development (85%): we'll focus on the recruitment of additional software developers, a graphic designer and a principal investigator/lead researcher; an important effort will be made to improve the integration of OncoStats with a number of IT ecosystems in order to benefit from a nearly "plug-and-play" approach in future sales to new institutions; the development of additional cancer modules (we started with breast cancer, next up is colon, gastric, lung and prostate cancer - approximately 3 months development per module); the development of the app that patients can take home during treatments to report adverse effects, receive support and keep in touch with their doctors.

- Develop our international expansion strategy (10% funding), establishing strategic partnerships with cancer treatment institutions with a focus in Europe, South America and Asia.

- Working Capital (5% funding).

Market

Target market

Our target market is public and private hospitals that treat cancer patients (software licenses and analytics reports). It is expected that pharmaceutical companies will enter as potential clients when partnerships form between them and the hospitals that use OncoStats for the creation of RWE data pipelines.

We are mainly interested in the European, Asian and South American markets. Our research suggests that these are markets characterized by basic or non-existent EMR systems, allowing for a more rapid expansion since integration with existing systems is simpler.

Characteristics of target market

Our company has identified 50 public cancer treatment institutions in Portugal and over 3000 in Europe (12 countries).

On a national level, we see Portugal as unique in Europe since the majority of all public hospitals use the same EMR, called SClinico®. It is developed by a government held company and it's a "one size fits all" EMR, which we think lacks any specific tools for cancer care.

Private hospitals in Portugal, which can be divided into 4 large groups (Luz Saúde, José de Mello Saúde, Lusíadas Saúde and Trofa Saúde) and each have their own distinct basic EMR system.

In Europe, in the general EMR market, Logica® and Tieto® are key players, but to our knowledge they lack specific solutions in Oncology.
We feel the there is an equal lack of independent Oncology specific tools. The ones that exist are usually developed in-house, tend to be rudimentary, serving only specific needs of that institution and do not have commercial aspirations.

EMRs that are key players in the US (e.g. Epic®, Cerner®, etc.) are also struggling to expand in Europe due to regional differences and government restrictions, and they also lack any differentiation in Oncology. Flatiron® is a success case in the Oncology space having acquired the largest Oncology specific EMR in the US and establishing several key partnerships, but are solely focused in US market.

Marketing strategy

There will be different approaches, one at the national level in Portugal and one at the international level.

First, we'd like to emphasize that the health IT market in Portugal is quite unique - the same EMR (SClinico) has a very large market share in public hospitals.

We see this as a clear advantage and Portugal is a perfect launch market for us. The pilot that we are currently running in a public hospital uses Sclinico and we are seeking a level of integration that will allow us to position OncoStats as a tool that complements Sclinico and we hope to be present in nearly every hospital in Portugal in the next 2 years.

In the private sector we have launched a pilot in a hospital from one the largest health groups in Portugal and we see this as a platform to expand to every other hospital in that group.

Pharmaceuticals can be important partners.
We believe that "word of mouth" between doctors and hospitals will be our most effective marketing tool, one that carries a very low cost and one that also works when expanding to international markets.

Our approach for international markets will be to develop strategical partnerships with cancer treatment institutions, reference names in oncology and pharmaceuticals.

As marketing strategies, we'll also focus on emotionally-compelling online and offline media; referral testimonials using video marketing with reference players in the medical industry.

Competition strategy

OncoStats is a software that is built "by doctors for doctors".

Since we focus so much on usability and user experience with oncologists, we understand exactly what their needs are and provide a tool, that not only is pleasing to be used but also one that suits their needs on a day-to-day basis.

Oncostats differentiation is determined by the:

- Quality of the information collected (standardized and clinically validated);

- Ability to co-exist and integrate with current hospital EMRs, addressing specific needs in Oncology that are otherwise ignored;

- Launch of the product in a "single EMR" market (Portugal) giving a strategic advantage;

- Integration with patient data, using an at-home app during ambulatory treatments, correlating the clinical side with patient-related outcomes.

We expect to have a lower entry price since we can negotiate licences based on individual cancer modules, lowering the barrier for sale. This means that a contract licence can be negotiated for a single module (e.g. Breast Cancer) and other modules can be added later at an additional cost.

Open an account to get access to the team members of OncoStats

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Open an account to get access to the OncoStats campaign updates

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Open an account to get access to the list of investors in the OncoStats campaign

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Open an account and verify your identity to get access to the OncoStats discussion

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Open an account and verify your identity to get access to the OncoStats pitch deck and other documents

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for OncoStats has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 21 November 2016 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from €2,250,000

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Seedrs.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel